Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Astec Lifesciences Ltd

| Audited Standalone Financial Results for the Quarter and Full Year Ending March 31, 2026

Report Source

⬤27th Apr 26

Summary : Astec LifeSciences reported significant net losses for FY26, despite a successful rights issue and unmodified audit opinion, with negative operating cash flow.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of materials consumed (Standalone FY26): Rs. 27,045.00 Lakhs
  2. Changes in inventories (Standalone FY26): Rs. 2,796.44 Lakhs
  3. Employee benefits expense (Standalone FY26): Rs. 6,290.81 Lakhs
  4. Finance costs (Standalone FY26): Rs. 3,456.76 Lakhs
  5. Depreciation and amortisation expense (Standalone FY26): Rs. 4,499.34 Lakhs
  6. Other expenses (Standalone FY26): Rs. 9,132.84 Lakhs
  7. Revenue from Operations (Standalone FY26): Rs. 44,814.56 Lakhs
  8. Revenue from Operations (Consolidated FY26): Rs. 44,814.56 Lakhs
  9. Net cash flow from operating activities (Standalone FY26): Rs. -8,059.10 Lakhs
  10. Net cash flow from investing activities (Standalone FY26): Rs. -1,513.00 Lakhs
  11. Net cash flow from financing activities (Standalone FY26): Rs. 2,362.46 Lakhs
  12. Net increase/(decrease) in cash and cash equivalents (Standalone FY26): Rs. 10.45 Lakhs
  13. Total Assets (Standalone FY26): Rs. 94,122.43 Lakhs
  14. Total Equity (Standalone FY26): Rs. 38,986.64 Lakhs
  15. Total Liabilities (Standalone FY26): Rs. 55,135.79 Lakhs
  16. Current Ratio (Standalone FY26): 0.88
  17. Net Worth (Standalone FY26): Rs. 38,986.64 Lakhs
  18. Debt Equity ratio (Standalone FY26): 1.15
  19. Total debts to total assets (Standalone FY26): 0.48
  20. Approval sought for Material Related Party Transactions for FY 2026-27.
  21. Both standalone and consolidated financial results are presented and audited.

Corporate Overview

  1. Significant net losses for the year and quarter.
  2. Negative operating and net profit margins.
  3. Impact of new Labour Codes on gratuity and long-term compensated absences.
  4. Agrochemicals manufacturing
  5. Formal and factual reporting of board decisions and financial results.
  6. Agrochemicals
  7. Rights Issue completed for capital infusion.

Risk Factors

  1. Significant net losses reported.
  2. Negative operating and net profit margins.
  3. Impact of new Labour Codes.
  4. Negative cash flow from operations.

Key Drivers

  1. Rights issue successfully completed.
  2. New board members appointed.
  3. Unmodified audit opinion received.
  4. Compliance with SEBI regulations.

Auditor’s Report

  1. Unmodified opinion on standalone and consolidated financial results.

Board Commentary

  1. Appointment of Mr. Vishal Sharma as Non-Executive Director.
  2. Appointment of Mr. Burjis N. Godrej as Non-Executive Director.
  3. Appointment and Remuneration of Mr. Arijit Mukherjee as Executive Director (COO).
  4. Appointment of Mr. Mathew Eipe as Independent Director.
  5. Incremental impact from new Labour Codes presented as 'Exceptional Items'.
  6. Compliance with SEBI Listing Regulations 30, 33, 52(4), and 63.
  7. Approval for Material Related Party Transactions for FY 2026-27.
  8. Rights Issue of 26,69,951 fully paid-up equity shares at Rs. 890 each.
  9. No deviation in use of Rights Issue proceeds from stated objects.

Corporate Governance

  1. Appointment of Independent Director and Non-Executive Directors proposed.
  2. Audit Committee and Rights Issue Committee are mentioned.

Management Discussion & Analysis

Risk Control Measures

  1. Monitoring finalisation of Central/State Rules for Labour Code impact.

Critical Risks

  1. Potential financial impact from new Labour Codes.
  2. Material Related Party Transactions require shareholder approval.